Broad genomic workup including optical genome mapping uncovers a *DDX3X: MLLT10* gene fusion in acute myeloid leukemia

Verena Nilius-Eliliwi¹, Marco Tembrink²†, Wanda Maria Gerding², Krzystof P. Lubieniecki², Joanna M. Lubieniecka², Stefanie Kankel³, Thomas Liehr³, Thomas Mika¹, Fotios Dimopoulos¹, Konstanze Döhner⁴, Roland Schroers¹, Hoa Huu Phuc Nguyen² and Deepak Ben Vangala¹*

¹Department of Medicine, Hematology and Oncology, Knappschaftskrankenhaus, Ruhr-University Bochum, Bochum, Germany, ²Human Genetics, Ruhr-University Bochum, Bochum, Germany, ³Jena University Hospital, Friedrich Schiller University, Institute of Human Genetics, Jena, Germany, ⁴Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany

In acute myeloid leukemia (AML), treatment decisions are currently made according to the risk classification of the European LeukemiaNet (ELN), which is based on genetic alterations. Recently, optical genome mapping (OGM) as a novel method proved to yield a genome-wide and detailed cytogenetic characterization at the time of diagnosis. A young female patient suffered from a rather unexpected aggressive disease course under FLT3 targeted therapy in combination with induction chemotherapy. By applying a “next-generation diagnostic workup” strategy with OGM and whole-exome sequencing (WES), a *DDX3X: MLLT10* gene fusion could be detected, otherwise missed by routine diagnostics. Furthermore, several aspects of lineage ambiguity not shown by standard diagnostics were unraveled such as deletions of *SUZ12* and *ARPP21*, as well as T-cell receptor recombination. In summary, the detection of this particular gene fusion *DDX3X: MLLT10* in a female AML patient and the findings of lineage ambiguity are potential explanations for the aggressive course of disease. Our study demonstrates that OGM can yield novel clinically significant results, including additional information helpful in disease monitoring and disease biology.

**KEYWORDS**

acute myeloid leukemia, optical genome mapping, *DDX3X, MLLT10*, FLT3-ITD, *SUZ12*, *ARPP21*, biphenotypic leukemia
Introduction

Acute myeloid leukemia (AML) is a common hematologic malignancy with a mortality rate of approximately 50% (1, 2). Treatment has improved in recent years with the introduction of new drugs that target specific proteins altered by distinct genetic aberrations. This progress and the increasing knowledge of risk stratification urge for more accurate genetic testing at diagnosis and relapse. Treatment decisions are currently made in line with the risk classification of the European LeukemiaNet (ELN), which is based on disease-specific genetic alterations (3).

In a recent study, we compared standard cytogenetic methods with optical genome mapping (OGM) as a novel diagnostic method for structural genome analysis in AML and myelodysplastic syndrome (MDS) (4). Briefly, ultrahigh-molecular weight (UHMW) DNA is prepared and labeled genome-wide and sequence-specific with a fluorochrome dye. After being loaded on a chip and linearized through nanochannels by electrophoresis, the labeled DNA is captured by a fluorescence microscope and processed by different software algorithms against the human GRCh37/hg19 labeling pattern. Furthermore, different pipelines are used to detect structural variants (SVs) and copy number variants (CNVs). The coverage of this method is about 300×, and the mosaicism detection level currently is about 2% for SVs and 8% for CNVs, with a substantial number of CNVs also covered in the SV pipeline (4). Besides a substantial gain of relevant information by OGM compared to classical karyotyping, here, we detected a DDX3X: MLLT10 gene fusion in a 21-year-old female AML patient. To our knowledge, this is the first time this aberration is described in a female patient. Strikingly, DDX3X is a gene that escapes X-inactivation in women (8). Accordingly, Brandimarte et al. (6) hypothesized that DDX3X translocations might be a leukemic driver due to the lack of a second gene copy in male individuals (6, 9). Apart from that, both genes, DDX3X and MLLT10, separately have been observed to play a role in a whole range of different hematologic and solid malignancies (10–12).

Based on cytomorphology, immunophenotypic analysis, and histopathology, the disease in our patient was classified as CD33+, CD34+, CD38+, CD117+ AML with aberrant CD7 expression. By OGM, different genetic alterations related to T-lineage commitment were unraveled. Interestingly, the disease course appeared to be worse than expected. To improve our understanding of the aberrations and their contribution to leukemogenesis, we further analyzed the bone marrow sample by fluorescence in situ hybridization (FISH), whole-exome sequencing (WES), and consecutive OGM analysis. The purpose of this report is to provide insights into the benefits of a “next-generation diagnostic workup” for hematologic diseases using two different genome-wide high-resolution technologies and to find out whether its application might result in additional information useful for clinical decision-making.

Methods

Genetic standard diagnostics, such as karyotyping and PCR panels, are presented in the Results section and were performed at the University Hospital Knappskraftkrankenhaus Bochum and in collaborating laboratories. The patient gave written informed consent for genetic diagnostics and publication of results.

Optical genome mapping

OGM was performed as part of a recently published study at the initial time point (first time point) of AML diagnosis with UHMW DNA was isolated using an isolation kit from Bionano Genomics following the manufacturer’s protocol. The DNA motif CTAAAG was labeled fluorescently by direct label and stain technology using a pattern recognition enzyme according to the manufacturer’s instructions [direct labeling enzyme 1 (DLE-1), Bionano Genomics]. Optical scans were performed on a Saphyr platform (Bionano Genomics) using a G2.3 chip. Raw molecule data generated by OGM from samples collected at two different time points were computed using the Rare Variant method (Bionano Solve v3.7) and analyzed by the latest Bionano Access release v1.7, adding allele frequency estimates for SVs and an optimized nomenclature. OGM data showed an effective post-analysis 403-fold coverage at the initial time point and a 395-fold coverage after induction therapy. Quality metrics were reached for both samples. GRCh37/hg19 human genome reference was used for alignment.

Output SVs and CNVs were filtered against masks for known regions of high variance and default confidence cutoffs in Bionano Access v1.7 (insertion 0, deletion 0, inversion 0.7, duplication -1, intra-fusion 0.05, inter-translocation 0.05). SVs were filtered for absence in a control population consisting of 179 healthy controls provided by the manufacturer (Bionano Genomics). The remaining SVs were evaluated for their confidence, uniqueness, gene annotation overlaps, and presence in the Database of Genomic Variants (DGV). T-cell receptor (TCR) loci SVs were reported without filtering against controls, as somatic mutations are part of physiological T-cell maturation processes. All CNVs after CNV mask filtering using
default confidence cutoffs (0.5 Mbp for size and 0.99 for confidence) were reported.

**Fluorescence in situ hybridization**

To confirm the gene fusion DDX3X: MLLT10, FISH analysis on interphase nuclei was performed. FISH probes were hybridized to bone marrow smears according to manufacturer’s instructions (MetaSystems, Altlussheim, Germany). A 193-kilobase probe covering the whole DDX3X locus including STS markers HUMSWX1304/RH1146 to DBX was synthesized (DDX3X-20-AQ; Empire Genomics), and a commercially available probe for the detection of KMT2A:: MLL10 [X; t (10;11) MLL10/KMT2A DF, MetaSystems, Altlussheim, Germany] was applied.

**Whole-exome sequencing**

A WES library was constructed using SureSelectXT Human All Exon V7 (Agilent Technologies) and sequenced on NovaSeq 6000 instrument (Illumina). Sequence alignment, variant calling, and annotation were performed using Varvis bioinformatics pipeline v1.20.0 (Limbus Medical Technologies). For evaluation of myeloid cancer-related mutations, the coding sequences of 54 genes based on a commercially available myeloid NGS panel (TruSight Myeloid Sequencing Panel, Illumina) and four case-specific genes based on OGM results (DDX3X, MLL10, NFI, SUZ12) were analyzed for SNVs and CNVs. All detected SNVs with a population frequency <1% in gnomAD database were extracted and rated according to current cancer sequence variant interpretation standards of AMP consensus for myeloid cancer-related genes. DDX3X: MLL10 breakpoint search was done using the Varvis alignment by manual inspection in Integrative Genome Viewer (IGV), and fusion was confirmed using BLAT search tool University of California Santa Cruz (UCSC) and Sanger Sequencing (3500xl. Genetic Analyzer, Applied Biosystems) (detailed information in Supplementary Material 1) (13, 14).

**T-cell receptor clonality and junction analysis**

To confirm clonal TCR TRD V(D)J recombination, Sanger sequencing was performed using primers for the amplification of TRDV1 and TRDJ1 generated using sequences of a EuroClonality-NGS validation study (sequences available upon request) (15). Sequencing was performed on a 3500xL Genetic Analyzer (Applied Biosystems). Sequence was analyzed using IMGT/V-Quest v3.5.29 incorporating TCR mutation junction analysis and reading frame evaluation (16).

**Results**

**Patient characteristics and disease course**

At initial diagnosis (first time point) in December 2020, the 21-year-old female patient presented with peripheral leukocytosis of $81 \times 10^9/L$ accompanied by thrombocytopenia concomitant to a bone marrow infiltration of >90% with myelomonocytic blasts including some Auer rods (Figures 1A, B). Immunohistological workup revealed a weak expression of lysozyme and myeloperoxidase. Flow cytometry showed the expression of CD3, CD34, CD38, HLA-DR, and CD117, as well as aberrant expression of CD7 (Figure 1C), CD1a, surface and cytosolic CD3, and TCR were not detected. Cytogenetics reported a normal karyotype in the bone marrow sample, but only three metaphases could be evaluated. Molecular fragment length analysis subsequent to PCR amplification showed FLT3-ITD high (ratio 0.759) and biallelic heterozygous CEBPA mutations. Fusion genes were not detected in a standard RT-PCR panel (Menotype AMLplexQS) and neither IDH1, IDH2, NPM1, FLT3-TKD (PCR/fragment length analysis) nor ASXL1, RUNX1, TP53 [next-generation sequencing (NGS)] mutations were reported.

Based on these initial diagnostic results, the patient was grouped as high risk according to ELN 2017 risk classification and included in a clinical trial receiving gilteritinib in addition to the standard “3 + 7” induction therapy (daunorubicin 180 mg/m² and cytarabine 1,400 mg/m²). Although not reaching a blast clearance after initial induction, the patient was allowed to stay on study and was reinduced with daunorubicin (180 mg/m²) and intermediate-dose cytarabine (12 g/m²). However, despite combining intensive chemotherapy and targeted FLT3-ITD treatment with a Tyrosine Kinase Inhibitor (TKI), complete remission could not be achieved by this approach and the patient showed a persistence of blasts of about 20% (second time point) similar immunophenotypic expression profile (Supplementary Figure S1). Thus, salvage therapy according to FLAG-Eto-protocol (fludarabine 150 mg/m², cytarabine 10 g/m², etoside 300 mg/m², granulocyte colony stimulating factor (G-CSF) starting day 10) was initiated. Fortunately, complete remission was reached, and after identification of an human leukocyte antigen (HLA)-matched unrelated donor, the patient proceeded to allogeneic hematopoietic stem cell transplantation (allo-HSCT) following conditioning treatment including fludarabine (150 mg/m²) and treosulfan (36 g/m²). Graft versus Host Disease (GvHD) prophylaxis consisted of antithymocyte globulin (ATG), methotrexate (MTX), and ciclosporin A. After recovering without any major complications, maintenance treatment with sorafenib was started.
FIGURE 1
Cytology and immunophenotyping at initial diagnosis. Cytology of bone marrow (A) and peripheral blood (B) at initial diagnosis showing a subtotal infiltration of myelomonocytic blasts (A) and a blast with an Auer rod (B). Immunophenotyping of bone marrow aspirate by flow cytometry (C) showing the gating strategy and relevant markers leading to the diagnosis of AML. ECD, extracellular domain; SSC, Side scatter; PE, Phycoerythrine; FITC, Fluoresceinisothiocyanate.
**TABLE 1 Clinical characteristics.**

|                         | First time point initial diagnosis | Second time point after reinduction therapy |
|-------------------------|-----------------------------------|-------------------------------------------|
| Leukocyte count/L       | $81 \times 10^9$                 | $5 \times 10^9$                           |
| Hb mmol/l               | 8.14                              | 6.09                                      |
| Thromocyte count/µl     | 99,000                            | 205,000                                  |
| Histopathology          | >90% blasts                       | 30% blasts                                |
| Cytology                | >90% blasts, single Auer rods     | 20% blasts, no Auer rods                  |
| Flow cytometry          | >90% blasts: CD33, CD34, CD38, HLA-DR, CD117, CD7 pos. | 12% blasts: CD33, CD34, CD38, HLA-DR, CD117 pos. |
|                         | CD1a, CD3, cyCD3 neg              | CD1a, CD3, cyCD3, CD7 neg                |
| Karyotyping             | 46.XX [3]                         | 46.XX [27]                               |
|                         |                                   | 0.05 FLT3-ITD<sup>hhi</sup>              |
| RT-PCR panel/Fragment length analysis | CEBPA mut. biallelic, heterozygous | CEBPA mut. biallelic, heterozygous |

Most important findings by standard diagnostics of both time points. RT-PCR panel covering the following aberrations FLT3-TKD, NPM1, CBFB-MYH11, RUNX1-RUNX1T1, PML-RARA, CEBPA, IDH1, IDH2, RCR-AML1, KMT2A-MLLT3.

Hb, hemoglobin; ITD, internal tandem duplication.

Interestingly, the patient developed hyperglycemia and was diagnosed with maturity-onset diabetes of the young (MODY) type 3 that correlated with the detection of a germline HNF1A variant (NM_000545.8 c.457C>T), previously rated as pathogenic using gene American College of Medical Genetics and Genomics (ACMG) criteria (17). Currently, 400 days after allo-HSCT, the patient is weaned off immunosuppressants, has recovered fully, and remains molecularly disease-free. Patient characteristics are summarized in Table 1.

**Optical genome mapping**

In consecutive analyses, 23 and 28 SVs that were absent in healthy control samples were identified in our patient. After sorting out SVs commonly present in the DGV, SVs with low confidence, duplicate SVs, and SVs not overlapping annotated genes, eight SVs remained. All of them were detected at both diagnostic time points. Variant allele frequencies (VAFs) of the SVs of interest ranged from 42% to 53% (first time point) and from 8% to 16% (second time point), corresponding to histologically estimated blast proportions were given as >90% and 20%–30%, respectively.

A balanced rearrangement overlapping MLLT10 and DDX3X was represented in OGM by five interchromosomal-translocation SVs and one intrachromosomal-translocation SV with VAFs between 45% and 53%. As revealed by OGM, a complex rearrangement involving three chromosomes was found, involving chromosomes X, 10, and 6, resulting in a 5'-DDX3X:MLLT10-3' gene fusion on X-chromosome visualized in Figures 2A, B. Segments of different sizes are exchanged between chromosome Xp (1.14 Mbp) and 10p (0.46 Mbp). Additionally, a deleted piece of 8.68 Mbp of chromosome 6q material was found to be inserted into the derivative chromosome 10p.

Furthermore, a 1.4-Mbp deletion including the Cosmic Cancer Gene Census hallmark genes NFI and SUZ12 was detected at both time points of OGM analysis (18). These SVs were also confirmed by corresponding copy number losses (manually detectable at the first and second time points but only called above the confidence threshold at the first time point due to the lower allele fraction at the second time point). Moreover, an 84-kbp SV deletion including the 5' part of ARPP21 was detected in 42% and 8% allele fraction at the first time point and second time point, respectively. The 3' region containing one of two different genomic loci for microRNA 128 (miRNA128-2) and a polymerase III intronic promoter region allowing for ARPP21-independent transcription were preserved (19, 20).

SVs of the TCR regions TRA(D), TRG, and TRB were analyzed without filtering against controls. At TRA(D) locus, two different SV deletions were identified at both time points with corresponding VAF proportions compared to histologically determined blast percentages. One of these SVs seemed to represent a somatic TRDV1-TRDJ1 V(D)J recombination. The TRG locus contained one matching SV deletion with VAFs of 96% and 49% at both time points, respectively, which were likely overestimated by the software (196 and 16 molecules representing SV). Insertion SVs found at the TRB locus were less meaningful (5 and 3 insertion SV calls).

Sanger sequencing confirmed the suspected TRDV1-TRDJ1 recombination. Sequence analysis using IMGT/V-Quest-tool called an out-of-frame/nonsense mutation and junction analysis suspected TRDD2 and TRDD3 involvement.

**Fluorescence in situ hybridization**

In order to confirm OGM results regarding the DDX3X:MLLT10 gene fusion, FISH analysis was performed on interphase nuclei for the visualization of MLLT10 and DDX3X.
loci (Figure 2C). Additionally, a probe for KMT2A was co-hybridized to examine a potent ial rearrangement involving MLLT10’s most common fusion partner KMT2A. These results confirmed the DDX3X: MLLT10 gene fusion without evidence for involvement of the KMT2A gene in this rearrangement.

**Whole-exome sequencing**

After filtering for coding mutations, sequencing errors, and occurrence in <1% of gnomAD, seven SNVs and one CNV remained after analysis of the Cancer Virtual Panel.

One N-terminal frameshift mutation in CEBPA was called by Varvis software [c.308dup; p.Gly104fs, 35.3% allele frequency (AF)]. Another N-terminal frameshift mutation in CEBPA was not called (minimum called AF 7% at high coverage) but visible in approximately 7% of reads of the alignment visualized in IGV (c.116_117delinsA; p.Pro39fs) (14).

The FLT3-ITD was called with an AF of 57.7%. A 1.37-Mbp spanning loss including NF1 and SUZ12 was also detected by Varvis software (CN 1, no mosaic). In the remaining copy of NF1, no mutations were detected. On the other hand, in SUZ12, a c.682C>T (p.Pro228Ser) missense mutation at AF of 89.7% was detected (tier 3 VUS), which is absent in gnomAD. This result corresponded to the CNV loss in >90% blast material.

Furthermore, an MLLT10:c.2665G>A p.Val889Met missense mutation in exon 21 (tier 3 VUS) was observed, which is extremely rare in gnomAD. Also, the DDX3X: MLLT10 genomic breakpoint in exon 4 (DDX3X) and intron 10 (MLLT10) was manually visible in the alignment and proven by Sanger sequencing.

Combining those genetic diagnostic methods led to the finding of several additional aberrations. DDX3X: MLLT10 gene fusion and deletions in NF1, SUZ12, and ARPP21 were detected with OGM and confirmed by WES. The FLT3-ITD and biallelic CEBPA mutation found by standard RT-PCR were confirmed by WES.

**FIGURE 2**

Detection of DDX3X: MLLT10 gene fusion by optical genome mapping at the first time point and confirmation by FISH analysis. (A) Circos Plot (left) and detailed chromosome view SV visualization (right) of DDX3X: MLLT10 in Bionano Access v1.7 (Translocation Confidence: inter: 0.65, intra: 0.3) filtered for absence in controls. (B) Schematic overview of structural rearrangement. A 0.46-Mbp fragment of Chr. 10p including MLLT10 is transferred to Chr. Xp, fusing it to DDX3X. Furthermore, on Chr. 10p, an 8.68-Mbp fragment of Chr. 6q and a 1.14-Mbp fragment of Xp are inserted. Next to this insertion, a 40-kbp fragment is deleted. Both insertions are inverted and not in frame. (C) Interphase FISH analysis on bone marrow smear demonstrates DDX3X: MLLT10 gene fusion. Red signals (corresponding to MLLT10 at 10p12.13) and blue signals (corresponding to DDX3X at Xp11.4) are visualized adjacently and are indicated by arrowheads. In addition, green KMT2A control signals are not located in proximity to red MLLT10 hybridization signals, indicating the lack of involvement of KMT2A in the structural rearrangement. Analyzed cell nuclei reveal heterogeneous hybridization signals due to subclonal events.
Discussion

Acute leukemias have undergone tremendous changes regarding diagnostics and to a lesser extent treatments over the last years. We have recently described OGM as a potential tool to detect SVs on a genome-wide level with sufficient depth and high concordance to currently used methods as classical karyotyping (4). By implementing OGM in our diagnostic algorithm in combination with WES as part of an exemplary next-generation diagnostic workup, we could detect a DDX3X:MLLT10 gene fusion, to the best of our knowledge, for the first time in a female AML patient. Both genes, DDX3X and MLLT10, have been previously described to be involved in hematological and non-hematological neoplasia (10, 11).

In detail, DDX3X has previously been described as a regulator of RNA metabolism (21). Its role as a tumor suppressor and simultaneously as an oncogenic driver is complex and yet to be fully understood (10). The helicase interacts with important key pathways including p53 and Kirsten rat sarcoma virus homologue (KRAS) (22–25). Somatic mutations were found in a variety of cancers including medulloblastoma and hematological neoplasia such as acute and chronic lymphocytic leukemia (26, 27). DDX3X appears to be epigenetically silenced in renal cell carcinoma and has been discussed as a potential therapeutic target (28, 29).

Rearrangements involving the MLLT10 gene are recurrent in ALL (more common in T-lineage ALL) and less often in AML (typically pediatric) (12, 30, 31). Regardless of the partner gene, MLLT10 rearrangements appear to be associated with an adverse outcome in AML (5). MLLT10 is involved in histone modification by regulating the function of the histone methyltransferase DOT1L, the only methyltransferase known to methylate H3K79. In MLLT10-rearranged leukemia, DOT1L induces the transcription of genes involved in cell cycle progression (especially genes in the Homeobox A Cluster) (32–34). This might in the future have clinical implications, as a recent phase I trial with pinometostat, as a specific inhibitor of DOT1L, showed some promising results (35).

As in most ALL cases, reports of DDX3X:MLLT10 fusions in AML are restricted to a few cases in male patients (5, 6). Apart from the DDX3X: MLLT10 gene fusion, OGM could also unravel deletions in ARPP21, NFI, and SUZ12. SUZ12 is part of the polycomb repressive complex 2 (PRC2) that in turn is responsible for the methylation of H3K27 (36, 37). This methylation enables DOT1L with its complex to bind and exert its function as a transcription initiator for H3K79 (34). Thus, the SUZ12 deletion and the DDX3X: MLLT10 gene fusion might act synergistically in histone modification and could explain the aggressive course of disease (Figure 3).

ARPP21 is known to positively regulate PHF6-mRNA. It has a physiological counterpart, miRNA128, which is among others located at the 3’ end of ARPP21 (20). OGM here clearly shows that the deletion does not affect miRNA128 and its intrinsic polymerase III-dependent open reading frame (19). Altogether, this might lead to a downregulation of PHF6-mRNA, which is a known tumor suppressor (38, 39).

Intriguingly, most of the findings uncovered by our next-generation diagnostic workup have rarely been associated with AML but are more common in early T-lineage ALL. In pediatric T-lineage ALL, DDX3X is the second most common fusion partner for MLLT10 after PICALM (40). Furthermore, SUZ12 and PHF6 have been described in the context of T-ALL, with PHF6 being one of the most frequently mutated or deleted genes in T-lymphoblastic leukemia and less often in AML and other myeloid neoplasia (38, 41, 42). Furthermore, OGM showed deletion SVs in the TCR regions representing clonal V(D)J recombinations. Clonal recombination of TRD and TRB could be indicative of an early stage in T-cell development. Combined with the immunophenotypic findings of CD34 and CD38 as well as lack of CD1a expression, these findings support the hypothesis that the leukemic blasts are in a pro-thymocyte (DN2) state (43, 44).

Lineage attribution today is mostly based on immunophenotyping, and AML and ALL are further classified according to genetic alterations relevant for further prognosis. This in turn leads to treatment protocols that 1) are lineage-specific, 2) are more or less intensive according to the genetic risk stratification, and 3) might include targeted therapies if actionable variants are detected. In the case described here, despite an aberrant CD7 expression in flow cytometry, routine diagnostics including cytology (Auer rods), immunohistostaining (myeloperoxidase and lysozyme expression), immunophenotyping by flow cytometry (Figure 1, Supplementary Figure S1), and the mutational profile (FLT3-ITD, CEBPA) led to the diagnosis of an AML. This is in line with the WHO 2016 classification, and even the older criteria of the European Group for the Immunological Classification of Leukemias (EGIL) would not have diagnosed a mixed-phenotype acute leukemia (MPAL) but an AML with aberrant coexpression of lymphatic markers due to the CD7 expression (45, 46). However, although being by far more prevalent in AML, neither Auer rods nor FLT3-ITD or CEBPA variants are exclusive to myeloid differentiation but have been previously described in ALL, especially in early T-cell precursor (ETP)-ALL (47–50).

In clinical practice, commitment to a diagnosis is necessary for defining the optimal treatment. Despite the arguably best available treatment protocol by adding FLT3-targeted therapy to standard “7 + 3” induction, treatment response was unsatisfying, without sufficient blast clearance. However, FLAG-containing regimens with consolidating allogenic transplantation and sorafenib maintenance treatment in case of activating FLT3...
mutations not only are regular salvage approaches in refractory AML but also have been described as a successful therapy in ETP-ALL (51).

The immunophenotypic profile (including immunohistochemistry and flow cytometry) in this case was indicative of a myeloid differentiation (Figure 1C, Figure 4). Treatment with FLAG-Eto as salvage therefore was a straightforward approach. Compared to that, the initial diagnosis of a T-lineage disease not only would have led to a different treatment protocol but also might have changed the approach in the treatment-refractory situation with substances such as nelarabine. Thus, our here proposed broad genomic workup utilizing whole-genome cytogenetics and WES might in the future lead to a more distinct classification of disease and might help to overcome the flaws of immunophenotyping in certain situations. The detection of genetic changes typical for myeloid and early lymphoid differentiation as presented here could hint to a stem cell-like myeloid-lymphoid precursor, as has been very recently proposed by Genescà and Starza (52). This in turn could lead to more personalized approaches in treatment, omitting unwanted toxicities and improving the outcome for the patient (53).

Without OGM as a whole genome-based method with high resolution and deep coverage, the DDX3X: MLLT10 gene fusion and other genetic aberrations not covered by routine diagnostics would have been missed. In this work, FISH, WES, and Sanger sequencing were applied as conformational diagnostics. Notably, the FISH probes used are far from any routine use. Thus, not only does OGM have the potential to improve the detection of novel aberrations but also it renders multiple other methods somewhat uncalled for.

In summary, by implementing OGM as a cytogenomic method, we detected SVs in genes involved in histone modification (DDX3X: MLLT10, SUZ12), offering a
functional explanation for aggressiveness of disease in this case. Furthermore, these and other detected variants (ARPP21, TCR variants) in combination with mutated myeloid genes also typical for ETP-ALL clearly hint lineage ambiguity, which was missed by routine diagnostic procedures relying on immunophenotyping for lineage discrimination. In conclusion, a next-generation diagnostic approach as proposed here has the potential to not only detect novel genetic variants but also improve risk stratification and thus individualized treatment.

**Ethics statement**

This study was reviewed and approved by Ethik-Kommission der Medizinischen Fakultät der Ruhr-Universität Bochum Gesundheitscampus 33. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

**Author contributions**

VN-E, MT, WG and DBV prepared the manuscript. FD, TM, VN-E, DBV, RS and KD collected patient data. KL, MT and JL analyzed WES data. TL and SK performed and analyzed FISH experiments. HN, RS and DBV contributed to conception and

**Data availability statement**

The data presented in the study are deposited under [http://zenodo.org](http://zenodo.org) under accession number 6421158 387.
design of the study. All authors contributed to the article and approved the submitted version.

Funding

We thank FORUM of the Faculty of Medicine at the Ruhr-University Bochum for funding MT (medical doctoral thesis program) and VN-E as part of the Female Clinician Scientist program.

Acknowledgments

Thanks to Iris Over for expert technical assistance and the patient for participating in the study.

Conflict of interest

DV received speaker’s honoraria from Roche, consultant’s honoraria from Pfizer, Bristol Myers Squibb and Gilead as well as travel support and congress registration fees from Gilead and Celgene.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.959243/full#supplementary-material

**SUPPLEMENTARY FIGURE 1**

Immunophenotyping of bone marrow aspirate from the second time point before salvage chemotherapy. Despite a visible neutrophile-cloud compared to initial diagnosis, the blast-population with a similar expression profile is still clearly visible.

**References**

1. Shah A, Andersson TML, Rachet B, Björkholt M, Lambert PC. Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study. Br J Haematol (2013) 162:509–16. doi: 10.1111/bjh.12452

2. Available at: https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2019/krebs_in_deutschland_2019.pdf?

3. Dischner H, Eiste E, Grimwade D, Amador S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 EAN recommendations from an international expert panel. Blood (2017) 129(6):424–47. doi: 10.1182/blood-2016-08-733196

4. Gerdinger WM, Tembrink M, Nilius-Eliliwi V, Mika T, Dimopoulos F, Ladigan-Badura S, et al. Optical genome mapping reveals additional prognostic information compared to conventional cytogenetics in AML/MDS patients. Int J Cancer (2022) 384(10):924–35. doi: 10.1002/ijc.33942

5. Ries RE, Leonti AR, Triche TJ, Gerbing RB, Hirsch BA, Raimondi SC, et al. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia (2019) 13:461–1. doi: 10.1182/blood-2019-125943

6. Brandimarte L, La Starza R, Gianfelici V, Barba G, Pierini V, di Giacomo D, et al. DDXX3X-MLLT10 fusion in adults with NOTCH1 positive T-cell acute lymphoblastic leukemia. Haematologica (2014) 99:64–6. doi: 10.3324/haematol.2013.101725

7. Brandimarte L, Pierini V, di Giacomo D, Borgia C, Nozza F, Gorello P, et al. New MLLT10 gene recombinations in pediatric T-acute lymphoblastic leukemia. Blood (2013) 121:5064–7. doi: 10.1182/blood-2013-02-487236

8. Yang F, Babak T, Shendure J, Disteche CM. Global survey of escape from X-inactivation by RNA-sequencing in mouse. Proc Natl Acad Sci U S A (2018) 115:1320–5. doi: 10.1073/pnas.1716049115

9. Yang F, Babak T, Shendure J, Disteche CM. Structure and activity of putative intronic miRNA promoters. Nucleic Acids Res (2018) 46:1708–16. doi: 10.1093/nar/gky1015

10. He Y, Zhang D, Yang Y, Wang X, Zhao X, Zhang P, et al. A double-edged function of DDXX3X as an oncogene or tumor suppressor, in cancer progression (Review). Oncol Rep (2018) 39:883–92. doi: 10.3892/or.2018.6203

11. Mo J, Liang H, Su C, Li P, Chen J, Zhang B. DDXX3X: structure, physiologic functions and cancer. Mol Cancer (2021) 20:1–20. doi: 10.1186/s12943-021-01325-7

12. Forgione MO, McClure BF, Yeung DT, Eadie LN, White DL. MLLT10 rearranged acute leukemia: Incidence, prognosis, and possible therapeutic strategies. Genes Chromosomes Cancer (2020) 59:709–21. doi: 10.1002/gcc.22887

13. Kent WJ. BLAT—the BLAST-like alignment tool. Genome Res (2002) 12:656–64. doi: 10.1101/gr.129202

14. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol (2011) 29:24–6. doi: 10.1038/ nb.1754

15. Brüggemann M, Kotrova M, Knecht H, Bartram J, Boudjogrha M, Bystrý V, et al. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia (2019) 33:2241–53. doi: 10.1038/s41375-019-0496-7

16. Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for integration and annotation of immunoglobulin and T-cell receptor V-D-J sequence analysis. Nucleic Acids Res (2008) 36:W503–8. doi: 10.1093/nar/gkn316

17. Albari S, Namj SA, Bennett AJ, Ackrurst I, Rundell J, Cokelaugh K, et al. Unsupervised Clustering of Missense Variants in HF11A Using Multidimensional Functional Data Aids Clinical Interpretation. Am J Hum Genet (2020) 107(4):670–82. doi: 10.1016/j.ajhg.2020.08.016

18. Tate JG, Bamford S, Jubb HC, Sondka Z, Beare DM, Bindal N, et al. COSMIC: the catalogue of somatic mutations in cancer. Nucleic Acids Res (2019) 47:D941–7. doi: 10.1093/nar/gky1015

19. Monteys AM, Spengler RM, Wan J, Tecedor L, Lennos KA, Xing Y, et al. Structure and activity of putative intronic miRNA promoters. RNA (2010) 16:495–505. doi: 10.1265/RNA.1731910

20. Rebhöld F, Matiscka D, Grosser S, Knaufl P, Eravci M, Vida I, et al. The RNA-binding protein ARPP21 controls dendritic branching by functionally opposing the miRNA it hosts. Nat Commun (2018) 9:1–13. doi: 10.1038/s41467-018-03681-3
